Gaucher disease phenotypes outflanked?

One of the major puzzles in modern human genetics is the fact that patients with the same genotype for a diseasecausing mutation may express very different clinical manifestations. Gaucher disease is one of the more common, clinically important, autosomal recessive disorders. In this issue, Winfield et al. (1997) point out that the problem of phenotypic variation is a serious one in this disorder and that understanding the cause of this variation is of great practical importance. Our ability to provide useful prenatal counseling is hampered by the variability of outcome, even when the genotype of the fetus has been established. The identification of three new genes close to the glucocerebrosidase (GBA) locus enriches our understanding of this important area of chromosome 1. But whether the presence of important genes adjacent to the GBA locus can explain the variability of the manifestations of Gaucher disease raises two distinct questions: The first concerns the cause of the variation that exists between individuals with the same genotype; and the second relates to the cause of the variation between patients who have different Gaucher disease genotypes. The first of these questions— patients with the same genotype—is the most vexing, because the difference between clinical expression of patients with different genotypes seems related, at least in part, to the severity of the glucocerebrosidase deficiency produced. To explain the differences between individuals who have the same GBA genotype we must consider the fact that such differences can occur within the context of three different circumstances: (1) in identical twins, in which case the cause of variability is most probably environmental; (2) in sibs, in which case the cause of variability can be environmental or genetic, but if genetic, is unlikely to be tightly linked to the GBA locus; and (3) between apparently unrelated members of the general population, in which case variation in genes linked to the GBA locus might be the cause. However, in the case of the common Gaucher disease mutations it is now clear that virtually all individuals with a given common mutation have inherited all of the same genes in the regions flanking the GBA locus. Another map of this region (Demina et al. 1997) indicates that the distance between the 58 ends of red cell/liver pyruvate kinase gene (PKLR) is 71 kb, well beyond the downstream loci identified by Winfield et al. (this issue). Polymorphic sites exist within the PKLR locus; a study of 195 Gaucher disease patients with the 1226G/1226G genotype, representing 390 chromosomes, showed that all had a 1/1 haplotype both in the GBA and the PKLR gene at nucleotide 1705. All 56 Gaucher disease patients who were 1226G/84GG compound heterozygotes manifested a 1/+ GBA haplotype and 55 of these were 1/+ at PKLR nucleotide 1705 (Glenn et al. 1994; Demina et al. 1997). These findings are supported by those of Cormand et al. (1997), who show a lack of crossovers at an even longer distance, extending over 3.2 cM. Although the common 1448C mutation occurs in the context of more than one haplotype, the 1448C mutation that occurs in Norbottnia is certainly of a single origin, and here, too, marked phenotypic variation occurs (Erikson 1986). Thus, the common Gaucher disease mutations are of recent origin, arising from common founders, and because of this virtually all patients are like brothers and sisters in that the flanking regions they have inherited are exactly the same. Accordingly, the variability in the phenotype of Gaucher disease patients is unlikely to be explained by mutations in the genes in the flanking regions. The possibility that a new mutation has arisen in one of these genes in the flanking region cannot be totally dismisssed, but is unlikely considering that the 1226 G mutation for example, is probably only between 500 and 2000 years old (Beutler 1997). Is there any other way in which these genes could explain variability in the Gaucher disease phenotype? Only if variation in expression of these genes resulted from environmental factors or unlinked regulatory genes. One cannot rule out such a possibility, but the same types of factors could be altering the expression of the GBA gene itself, so it does not seem necessary to involve genes in the flanking regions. A more plausible case may be made to explain the phenotypes caused by different GBA mutations on the basis of mutations occurring in the tightly linked flanking genes. One need not invoke such an explanation for most Gaucher disease mutations because the reason that some mutations are mild and some severe is often obvious. The 84GG mutation, which has very severe phenotypic consequences and appears, on the basis of population data, to be lethal in the homozygous state, causes a frameshift in the leader sequence and prevents the formation of any enzyme. The 1448C mutation, which is associated with severe disease, results in a substitution of a helix-terminating proline for a leucine (L444P), but the 1226G (N370S) mutation results in the formation of fairly abundant, although kinetically abnormal, enzyme (van Weely et al. 1993) and would, therefore, be expected to have a milder effect. A further finding, compatible with the explanation that variation in phenotype is the result of the mutations in the GBA gene itself, comes from the fact that there is usually less residual activity in the leukocytes of patients with type 2 and type 3 disease than in type 1 disease (Beutler et al. 1984; Meivar-Levy et al. 1994). However, there is at least one clinical syndrome that is difficult to explain on the basis of decrease in glucocerebrosidase activity alone, and Mistry (1995) has already proposed that this mutation may E-MAIL [email protected]; FAX (619) 7842083. Insight/Outlook